Nasus Pharma NSRX
NYSE NSRX
$3.82 +0.13 (+3.40%)
As of: Oct 1, 2026 · 3:59 PM EDT

Nasus Pharma (NSRX) Liabilities and Shareholders Equity (2024 - 2026)

Updated

Nasus Pharma (NSRX) recorded Liabilities and Shareholders Equity of $12.45 million in Q2 2026, compared with $639,000 a year earlier.

Analysis

Nasus Pharma (NSRX) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends

At the end of FY2025, Nasus Pharma reported Liabilities and Shareholders Equity of $5 million, up 597.9% from FY2024.

  • Across earlier years, Liabilities and Shareholders Equity came in at $717,000 in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Nasus Pharma 33.27 Mn 33.27 Mn - 12.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 12.45 Mn
Dec 31, 2025 5.00 Mn
Jun 30, 2025 639,000.00
Dec 31, 2024 717,000.00
API Access

Nasus Pharma Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=NSRX&period=max&api_key=YOUR_API_KEY